Johannes D. Smeijer
Groningen, GR, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis.
Journal: European heart journal
Published: July 24, 2026
Finerenone in Persons with Chronic Kidney Disease without Diabetes.
Journal: The New England journal of medicine
Published: June 05, 2026
Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).
Journal: Lancet (London, England)
Published: April 23, 2026
Urinary clusterin as a biomarker of human kidney disease progression and response to the endothelin receptor antagonist atrasentan: An exploratory analysis from the SONAR trial.
Journal: Nature communications
Published: February 28, 2025
Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease.
Journal: Diabetes, obesity & metabolism
Published: February 18, 2025
Authors' Reply: Effects of Zibotentan and Dapagliflozin on Fluid Retention in Patients with CKD: Need More Evidence.
Journal: Journal of the American Society of Nephrology : JASN
Published: January 10, 2025
Endothelin receptor antagonists in chronic kidney disease.
Journal: Nature reviews. Nephrology
Published: October 30, 2024
Sex differences in response to the endothelin receptor antagonist atrasentan in individuals with type 2 diabetes and chronic kidney disease: a post hoc analysis of the SONAR trial.
Journal: Diabetologia
Published: July 11, 2024
The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease.
Journal: Diabetes, obesity & metabolism
Published: June 02, 2024
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.
Journal: Journal of the American Society of Nephrology : JASN
Published: March 25, 2024
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Journal: Kidney international
Published: May 17, 2023
Last Updated: 09/26/2026